BRAF and neoplasm: If the tumor has BRAF V600-activating mutation, BRAF inhibitor combined with MEK inhibitor is preferred (e.g., dabrafenib/trametinib, vemuragfenib/cobimetinib, and encorafenib/binimetinib; category 1, high-level evidence).